Literature DB >> 27222762

Probable Nootropicinduced Psychiatric Adverse Effects: A Series of Four Cases.

Farid Talih1, Jean Ajaltouni1.   

Abstract

The misuse of nootropics-any substance that may alter, improve, or augment cognitive performance, mainly through the stimulation or inhibition of certain neurotransmitters-may potentially be dangerous and deleterious to the human brain, and certain individuals with a history of mental or substance use disorders might be particularly vulnerable to their adverse effects. We describe four cases of probable nootropic-induced psychiatric adverse effects to illustrate this theory. To the best of our knowledge this has not been previously reported in the formal medical literature. We briefly describe the most common classes of nootropics, including their postulated or proven methods of actions, their desired effects, and their adverse side effects, and provide a brief discussion of the cases. Our objective is to raise awareness among physicians in general and psychiatrists and addiction specialists in particular of the potentially dangerous phenomenon of unsupervised nootropic use among young adults who may be especially vulnerable to nootropics' negative effects.

Entities:  

Keywords:  Nootropics; cognitive enhancers; psychiatric adverse effects; substance abuse; substance misuse; supplements

Year:  2015        PMID: 27222762      PMCID: PMC4756795     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  23 in total

1.  Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks.

Authors:  T Satou; T Itoh; Y Tamai; H Ohde; A J Anderson; S Hashimoto
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

Review 2.  Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials.

Authors:  J Thome; E Doppler
Journal:  Drugs Today (Barc)       Date:  2012-04       Impact factor: 2.245

3.  Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project.

Authors:  Ornella Corazza; Sulaf Assi; Pierluigi Simonato; John Corkery; Francesco Saverio Bersani; Zsolt Demetrovics; Jacqueline Stair; Suzanne Fergus; Cinzia Pezzolesi; Manuela Pasinetti; Paolo Deluca; Colin Drummond; Zoe Davey; Ursula Blaszko; Jacek Moskalewicz; Barbara Mervo; Lucia Di Furia; Maggi Farre; Liv Flesland; Agnieszka Pisarska; Harry Shapiro; Holger Siemann; Arvid Skutle; Elias Sferrazza; Marta Torrens; F Sambola; Peer van der Kreeft; Norbert Scherbaum; Fabrizio Schifano
Journal:  Hum Psychopharmacol       Date:  2013-07       Impact factor: 1.672

4.  Cognitive enhancing effects of modafinil in healthy volunteers.

Authors:  Danielle C Turner; Trevor W Robbins; Luke Clark; Adam R Aron; Jonathan Dowson; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2002-11-01       Impact factor: 4.530

5.  Cognitive enhancement following acute losartan in normotensive young adults.

Authors:  Rasha Mechaeil; Paul Gard; Anne Jackson; Jennifer Rusted
Journal:  Psychopharmacology (Berl)       Date:  2011-04-12       Impact factor: 4.530

6.  Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies.

Authors:  Mona Darwish; Mary Kirby; Edward T Hellriegel; Philmore Robertson
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

7.  Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain.

Authors:  S A Cohen; W E Müller
Journal:  Pharmacology       Date:  1993-10       Impact factor: 2.547

8.  Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases.

Authors:  H-J Cho; Y J Kim
Journal:  Methods Find Exp Clin Pharmacol       Date:  2009-04

9.  Effect of armodafinil on cortical activity and working memory in patients with residual excessive sleepiness associated with CPAP-Treated OSA: a multicenter fMRI study.

Authors:  Douglas N Greve; Stephen P Duntley; Linda Larson-Prior; Andrew D Krystal; Michele T Diaz; Sean P A Drummond; Stephen G Thein; Clete A Kushida; Ronghua Yang; Robert J Thomas
Journal:  J Clin Sleep Med       Date:  2014-02-15       Impact factor: 4.062

10.  Piracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intake.

Authors:  F Brandão; M M Paula-Barbosa; A Cadete-Leite
Journal:  Alcohol       Date:  1995 May-Jun       Impact factor: 2.405

View more
  3 in total

1.  Extract of Xylopia aethiopica and its kaurene diterpene, xylopic acid, improve learning and memory in mice.

Authors:  Awo Efua Koomson; Kennedy Kwami Edem Kukuia; Patrick Amoateng; Robert Peter Biney; Thomas Amatey Tagoe; Jeffrey Amoako Mensah; Elvis Ofori Ameyaw; Joseph Torbi; Seth Kwabena Amponsah
Journal:  IBRO Neurosci Rep       Date:  2022-03-29

2.  Influence of psychostimulants and opioids on epigenetic modification of class III histone deacetylase (HDAC)-sirtuins in glial cells.

Authors:  Kalaiselvi Sivalingam; Mayur Doke; Mansoor A Khan; Thangavel Samikkannu
Journal:  Sci Rep       Date:  2021-10-29       Impact factor: 4.379

Review 3.  Neuronutraceuticals Combating Neuroinflammaging: Molecular Insights and Translational Challenges-A Systematic Review.

Authors:  Shakta Mani Satyam; Laxminarayana Kurady Bairy
Journal:  Nutrients       Date:  2022-07-23       Impact factor: 6.706

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.